Colorectal Cancer Screening Strategies and Diagnostic Techniques

The early detection of colorectal cancer (CRC) is a critical determinant of patient outcomes, with screening programmes aimed at identifying premalignant lesions or early-stage disease. Traditional strategies include colonoscopy, which remains the gold standard due to its high sensitivity and capacity for polypectomy, and stool-based tests such as the faecal immunochemical test (FIT) that detect occult blood. Recent advances focus on molecular and technological innovations to improve non-invasive diagnostics. Multi-target stool DNA testing combines assessment of genetic and epigenetic alterations with haemoglobin detection to enhance sensitivity for both adenomas and carcinomas. Parallel development of advanced imaging modalities, including high-resolution endoscopy and narrow-band imaging, aims to reduce missed lesions, particularly in the proximal colon. Emerging techniques leverage microfluidic platforms for rapid biomarker analysis and integrate artificial intelligence (AI)-driven image interpretation to refine risk stratification and personalise screening intervals. Globally, these approaches seek to balance accessibility, cost-effectiveness and diagnostic accuracy to reduce CRC morbidity and mortality.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Colorectal Cancer Screening Strategies and Diagnostic Techniques publication trend

The graph below shows the total number of articles in colorectal cancer screening strategies and diagnostic techniques across all publications each year (not limited to Nature Index journals).

Technical terms

Microfluidic device: A miniaturised system that manipulates small fluid volumes to analyse multiple biomarkers rapidly.

Biomarker: A measurable molecular indicator of a biological state or disease, used for diagnosis or monitoring.

Tyrosine kinase inhibitor: A targeted therapeutic agent that blocks specific enzymes involved in cancer cell signalling.

Stool DNA test: A non-invasive assay that detects genetic and epigenetic tumour markers alongside stool haemoglobin.

Faecal immunochemical test (FIT): A screening tool that detects human haemoglobin in stool to identify colorectal bleeding.

Adenoma: A benign glandular tumour that can be a precursor lesion for colorectal cancer.

References

1. Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics. Biosensors (2023).
2. Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer. Frontiers in Pharmacology (2023).
3. Proteins in stool as biomarkers for non‐invasive detection of colorectal adenomas with high risk of progression. The Journal of Pathology (2020).
4. Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy. The American Journal of Gastroenterology (2020).
5. Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance. Current Treatment Options in Gastroenterology (2020).
6. A Practical Overview of the Stool DNA Test for Colorectal Cancer Screening. Clinical and Translational Gastroenterology (2022).
7. Faecal Diagnostic Biomarkers for Colorectal Cancer. Cancers (2021).